Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington. Show more
Location: 107 Spring Street, Seattle, WA, 98104, United States | Website: https://www.atossatherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
106.2M
52 Wk Range
$0.55 - $1.66
Previous Close
$0.82
Open
$0.81
Volume
495,139
Day Range
$0.81 - $0.84
Enterprise Value
48.32M
Cash
57.86M
Avg Qtr Burn
-6.255M
Insider Ownership
0.07%
Institutional Own.
21.17%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
(Z)-endoxifen + Abemaciclib (VERZENIO®) Details Cancer, Breast cancer | Phase 2 Data readout | |
(Z)-endoxifen Details Cancer, Ductal Carcinoma In Situ | Phase 2 Data readout | |
AT-301 Details COVID-19 | Failed Discontinued | |
AT-H201 Details COVID-19 | Failed Discontinued |